The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity

Hyo Jin Park, Yong Ran, Joo In Jung, Oliver Holmes, Ashleigh R. Price, Lisa Smithson, Carolina Ceballos-Diaz, Chul Han, Michael S. Wolfe, Yehia Daaka, Andrey Ryabinin, Seong Hun Kim, Richard L. Hauger, Todd E. Golde, Kevin M. Felsenstein

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The biological underpinnings linking stress to Alzheimer's disease (AD) risk are poorly understood. We investigated how corticotrophin releasing factor (CRF), a critical stress response mediator, influences amyloid-β (Aβ) production. In cells, CRF treatment increases Aβ production and triggers CRF receptor 1 (CRFR1) and γ-secretase internalization. Co-immunoprecipitation studies establish that γ-secretase associates with CRFR1; this is mediated by β-arrestin binding motifs. Additionally, CRFR1 and γ-secretase co-localize in lipid raft fractions, with increased γ-secretase accumulation upon CRF treatment. CRF treatment also increases γ-secretase activity in vitro, revealing a second, receptor-independent mechanism of action. CRF is the first endogenous neuropeptide that can be shown to directly modulate γ-secretase activity. Unexpectedly, CRFR1 antagonists also increased Aβ. These data collectively link CRF to increased Aβ through γ-secretase and provide mechanistic insight into how stress may increase AD risk. They also suggest that direct targeting of CRF might be necessary to effectively modulate this pathway for therapeutic benefit in AD, as CRFR1 antagonists increase Aβ and in some cases preferentially increase Aβ42 via complex effects on γ-secretase.

Original languageEnglish (US)
Pages (from-to)1674-1686
Number of pages13
JournalEMBO Journal
Volume34
Issue number12
DOIs
StatePublished - Jun 12 2015

Fingerprint

Amyloid Precursor Protein Secretases
Corticotropin-Releasing Hormone
Neuropeptides
Amyloid
Alzheimer Disease
Arrestin
Immunoprecipitation
CRF receptor type 1
Lipids

Keywords

  • Amyloid-β
  • Corticotrophin releasing factor
  • Stress
  • β-arrestin
  • γ-secretase

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)

Cite this

Park, H. J., Ran, Y., Jung, J. I., Holmes, O., Price, A. R., Smithson, L., ... Felsenstein, K. M. (2015). The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity. EMBO Journal, 34(12), 1674-1686. https://doi.org/10.15252/embj.201488795

The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity. / Park, Hyo Jin; Ran, Yong; Jung, Joo In; Holmes, Oliver; Price, Ashleigh R.; Smithson, Lisa; Ceballos-Diaz, Carolina; Han, Chul; Wolfe, Michael S.; Daaka, Yehia; Ryabinin, Andrey; Kim, Seong Hun; Hauger, Richard L.; Golde, Todd E.; Felsenstein, Kevin M.

In: EMBO Journal, Vol. 34, No. 12, 12.06.2015, p. 1674-1686.

Research output: Contribution to journalArticle

Park, HJ, Ran, Y, Jung, JI, Holmes, O, Price, AR, Smithson, L, Ceballos-Diaz, C, Han, C, Wolfe, MS, Daaka, Y, Ryabinin, A, Kim, SH, Hauger, RL, Golde, TE & Felsenstein, KM 2015, 'The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity', EMBO Journal, vol. 34, no. 12, pp. 1674-1686. https://doi.org/10.15252/embj.201488795
Park, Hyo Jin ; Ran, Yong ; Jung, Joo In ; Holmes, Oliver ; Price, Ashleigh R. ; Smithson, Lisa ; Ceballos-Diaz, Carolina ; Han, Chul ; Wolfe, Michael S. ; Daaka, Yehia ; Ryabinin, Andrey ; Kim, Seong Hun ; Hauger, Richard L. ; Golde, Todd E. ; Felsenstein, Kevin M. / The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity. In: EMBO Journal. 2015 ; Vol. 34, No. 12. pp. 1674-1686.
@article{1c3a792e836a47d59702b97a06edecaa,
title = "The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity",
abstract = "The biological underpinnings linking stress to Alzheimer's disease (AD) risk are poorly understood. We investigated how corticotrophin releasing factor (CRF), a critical stress response mediator, influences amyloid-β (Aβ) production. In cells, CRF treatment increases Aβ production and triggers CRF receptor 1 (CRFR1) and γ-secretase internalization. Co-immunoprecipitation studies establish that γ-secretase associates with CRFR1; this is mediated by β-arrestin binding motifs. Additionally, CRFR1 and γ-secretase co-localize in lipid raft fractions, with increased γ-secretase accumulation upon CRF treatment. CRF treatment also increases γ-secretase activity in vitro, revealing a second, receptor-independent mechanism of action. CRF is the first endogenous neuropeptide that can be shown to directly modulate γ-secretase activity. Unexpectedly, CRFR1 antagonists also increased Aβ. These data collectively link CRF to increased Aβ through γ-secretase and provide mechanistic insight into how stress may increase AD risk. They also suggest that direct targeting of CRF might be necessary to effectively modulate this pathway for therapeutic benefit in AD, as CRFR1 antagonists increase Aβ and in some cases preferentially increase Aβ42 via complex effects on γ-secretase.",
keywords = "Amyloid-β, Corticotrophin releasing factor, Stress, β-arrestin, γ-secretase",
author = "Park, {Hyo Jin} and Yong Ran and Jung, {Joo In} and Oliver Holmes and Price, {Ashleigh R.} and Lisa Smithson and Carolina Ceballos-Diaz and Chul Han and Wolfe, {Michael S.} and Yehia Daaka and Andrey Ryabinin and Kim, {Seong Hun} and Hauger, {Richard L.} and Golde, {Todd E.} and Felsenstein, {Kevin M.}",
year = "2015",
month = "6",
day = "12",
doi = "10.15252/embj.201488795",
language = "English (US)",
volume = "34",
pages = "1674--1686",
journal = "EMBO Journal",
issn = "0261-4189",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity

AU - Park, Hyo Jin

AU - Ran, Yong

AU - Jung, Joo In

AU - Holmes, Oliver

AU - Price, Ashleigh R.

AU - Smithson, Lisa

AU - Ceballos-Diaz, Carolina

AU - Han, Chul

AU - Wolfe, Michael S.

AU - Daaka, Yehia

AU - Ryabinin, Andrey

AU - Kim, Seong Hun

AU - Hauger, Richard L.

AU - Golde, Todd E.

AU - Felsenstein, Kevin M.

PY - 2015/6/12

Y1 - 2015/6/12

N2 - The biological underpinnings linking stress to Alzheimer's disease (AD) risk are poorly understood. We investigated how corticotrophin releasing factor (CRF), a critical stress response mediator, influences amyloid-β (Aβ) production. In cells, CRF treatment increases Aβ production and triggers CRF receptor 1 (CRFR1) and γ-secretase internalization. Co-immunoprecipitation studies establish that γ-secretase associates with CRFR1; this is mediated by β-arrestin binding motifs. Additionally, CRFR1 and γ-secretase co-localize in lipid raft fractions, with increased γ-secretase accumulation upon CRF treatment. CRF treatment also increases γ-secretase activity in vitro, revealing a second, receptor-independent mechanism of action. CRF is the first endogenous neuropeptide that can be shown to directly modulate γ-secretase activity. Unexpectedly, CRFR1 antagonists also increased Aβ. These data collectively link CRF to increased Aβ through γ-secretase and provide mechanistic insight into how stress may increase AD risk. They also suggest that direct targeting of CRF might be necessary to effectively modulate this pathway for therapeutic benefit in AD, as CRFR1 antagonists increase Aβ and in some cases preferentially increase Aβ42 via complex effects on γ-secretase.

AB - The biological underpinnings linking stress to Alzheimer's disease (AD) risk are poorly understood. We investigated how corticotrophin releasing factor (CRF), a critical stress response mediator, influences amyloid-β (Aβ) production. In cells, CRF treatment increases Aβ production and triggers CRF receptor 1 (CRFR1) and γ-secretase internalization. Co-immunoprecipitation studies establish that γ-secretase associates with CRFR1; this is mediated by β-arrestin binding motifs. Additionally, CRFR1 and γ-secretase co-localize in lipid raft fractions, with increased γ-secretase accumulation upon CRF treatment. CRF treatment also increases γ-secretase activity in vitro, revealing a second, receptor-independent mechanism of action. CRF is the first endogenous neuropeptide that can be shown to directly modulate γ-secretase activity. Unexpectedly, CRFR1 antagonists also increased Aβ. These data collectively link CRF to increased Aβ through γ-secretase and provide mechanistic insight into how stress may increase AD risk. They also suggest that direct targeting of CRF might be necessary to effectively modulate this pathway for therapeutic benefit in AD, as CRFR1 antagonists increase Aβ and in some cases preferentially increase Aβ42 via complex effects on γ-secretase.

KW - Amyloid-β

KW - Corticotrophin releasing factor

KW - Stress

KW - β-arrestin

KW - γ-secretase

UR - http://www.scopus.com/inward/record.url?scp=84930871482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930871482&partnerID=8YFLogxK

U2 - 10.15252/embj.201488795

DO - 10.15252/embj.201488795

M3 - Article

C2 - 25964433

AN - SCOPUS:84930871482

VL - 34

SP - 1674

EP - 1686

JO - EMBO Journal

JF - EMBO Journal

SN - 0261-4189

IS - 12

ER -